Valion Bio, Inc.
Income Statement
| Line Item | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $780.0K | $1.2M | $1.8M | $1.3M |
| Cost of Revenue | $778.0K | $889.0K | $1.5M | $1.3M |
| Gross Profit | $2.0K | $287.0K | $299.0K | $-38.0K |
| Gross Margin | 0.3% | 24.4% | 16.3% | -3.0% |
| Operating Expenses | ||||
| Research & Development | $1.3M | $1.7M | $1.7M | $878.0K |
| SG&A Expense | $3.2M | $4.8M | $5.9M | $2.9M |
| Operating Income | $-4.5M | $-8.2M | $-10.1M | $-5.6M |
| Operating Margin | -573.8% | -701.1% | -548.8% | -448.1% |
| Interest Expense | — | — | — | — |
| Pretax Income | — | $-8.2M | $-10.1M | — |
| Income Tax Expense | $0 | — | — | — |
| Net Income | $-5.7M | $-8.2M | $-10.1M | $-8.5M |
| Net Margin | -725.0% | -701.0% | -548.7% | -675.7% |
| EPS (Basic) | $-19.68 | $-44.20 | $-4.35 | $-0.10 |
| EPS (Diluted) | $-4.92 | $-44.20 | $-4.35 | $-0.10 |
| Shares Outstanding (Basic) | 287.4K | 186.6K | 2.3M | 83.8M |
| Shares Outstanding (Diluted) | 1.1M | 186.6K | 2.3M | 83.8M |
| Dividends Per Share | — | — | — | — |